BioSpace News Archive

The popularity of various formulations in the fixed dose combination drugs market stems largely from the fact that they hold great promise in improving adherence to long-term multi-drug therapies.

There has been an unmet need for advanced scaffold and patch materials for cardiac repairs among congenital heart surgeons across the world, hampering the outcome in several advanced cardiovascular surgeries.

The wave behind commercialization of cannabis cultivation largely pivots on legalization of recreational cannabis, most notably in the U.S. and Canada.

Technological advancement in custom 3D printed orthopedic implants and high demand for robotic mildly invasive surgical tools are driving the orthopedic implant sales.

Biophytis SA, a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, provides updates and perspectives on its Sarconeos programs ahead of its upcoming General Assembly on April 26, 2021.

BD, a leading global medical technology company, announced it has submitted a 510 premarket notification to the U.S. Food and Drug Administration for the BD Alaris™ System, the most widely used infusion pump in acute care hospitals across the United States.

AdaptHealth Corp., a national leader in providing patient-centric and technology-enabled chronic disease management solutions including home healthcare equipment, medical supplies to the home and related services in the United States announced that it has amended its senior secured credit facilities to increase its term loan by $100 million and to expand the maximum borrowing capacity under its revolving credit facility from $250 million to $450 million.

100% Renewable Energy Goal to be Achieved 15 Years Ahead of Schedule; Includes Three New Virtual Power Purchase Agreements

Amydis Inc., a leading ocular tracer biotechnology company with a broad portfolio of diagnostic candidates for detection of neurodegenerative diseases in the eye, announced completion of pre-IND interaction with the U.S. Food and Drug Administration regarding the current development plan for a small-molecule retinal tracer for the diagnosis of α-synucleinopathies.

Nephros , Inc. (Nasdaq: NEPH), a leading water technology company, today announced that it will file its first quarter financial results on Thursday, May 6, 2021 after market close and will host a conference call that same day at 4:30 PM ET.